NCT07047638

A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine

A Randomized, Evaluator-blinded, No-treatment Controlled, Multicenter Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine for Improvement in Skin Quality of the Face

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 171 (estimated)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, evaluator-blinded, no-treatment controlled, study to evaluate the effectiveness and safety of Restylane Skinboosters Vital Lidocaine treatment to improve skin quality of the face in China. Subjects of Chinese origin, age 18 years, who are eligible for treatment to improve skin quality of the face. Study center is up to 8. A total of approximately 171 subjects will be randomized (2:1) to either treatment with Restylane Skinboosters Vital Lidocaine Treatment Group (approximately 114 subjects) or no-treatment Control Group (approximately 57 subjects).

Conditions

• Skin Quality Improvement

Interventions

Type	Name	Description
DEVICE	Restylane Skinboosters Vital Lidocaine	Restylane Skinboosters Vital Lidocaine is an injectable, sterile, transparent, biodegradable gel of non-animal crosslinked sodium hyaluronate. Restylane Skinboosters Vital Lidocaine has the addition of lidocaine hydrochloride. They are supplied in a glass syringe.

Timeline

• Start date: 2025-07-09
• Primary completion: 2026-05-31
• Completion: 2027-07-31
• First posted: 2025-07-02
• Last updated: 2026-03-12

Locations

1 site across 1 country: China